The FDA approved Eli Lilly’s Lyumjev™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL) last month, which is a new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes. The approval was based on two phase 3 clinical trials based on comparison of Lyumjev and Humalog (insulin lispro injection, 100 units/mL). Lyumjev demonstrated superior reduction in blood glucose spikes at both one hour and two hours after a test meal as compared to Humalog. The interactive Multichannel News Release can be found here.
This the second insulin product approved by the FDA in June.